Scale check. 30% of US citizens is about 100 million people on a prescription weight-loss drug at the same time. The best survey numbers: KFF's May 2024 poll found 12% of adults had ever taken a GLP-1 drug and 6% were taking one at the time, for any reason including diabetes, and adults are about 77% of the population, so current use across all citizens was around 5% then. What has changed since: TrumpRx prices of about $350 a month for Wegovy and Zepbound in 2026, Medicare coverage for obesity at a $50 copay from July 2026 (BMI 35 or more, or 27 with comorbidities), an oral GLP-1, and generic semaglutide in Canada but not in the US, where the patents run into the 2030s. Eligibility is the ceiling that matters: 40% of US adults have obesity (NHANES), roughly 100 million people, so 30% of all citizens on the drugs means essentially every eligible adult plus some children, simultaneously, by mid-2031. Uptake roughly doubled in two years; it would need to multiply by six and then hold. 22% is generous, and the number to watch is KFF's current-use figure crossing 15%, which would be the first sign the line bends that far.

https://www.visualcapitalist.com/ranked-the-most-prescribed-drugs-in-the-u-s/

Currently, the most prescribed drugs is Lipitor with 7% of US adults being on it.

https://twitter.com/RosieCampbell/status/1636049465093296130